Search results

  1. V.R.T.

    MRC/NIHR DecodeME Showcase meeting online and in person Nov 6th

    Yes I was thinking along those sorts of lines too. And in a lot of ways those sorts of studies would have a quite compelling fundraising hook. That's reassuring to hear. Are things falling into place on that front then or is there more that needs to be done?
  2. V.R.T.

    Review AMPA receptors in the synapse: Very little space and even less time, 2021, Baranovic

    Should somebody reach out to this researcher? Seems like an ideal candidate to get interested in MECFS...
  3. V.R.T.

    MRC/NIHR DecodeME Showcase meeting online and in person Nov 6th

    Are there any smaller studies following on from DecodeME or other important stuff that could benefit from fundraising?
  4. V.R.T.

    MRC/NIHR DecodeME Showcase meeting online and in person Nov 6th

    Yes although that is in will-it-wont-it limbo with government funding. Unless anyone has an update? How long do we think until we know whats happening there. It's hard to effectively fundraise for something when you don't know how much you're asking for.
  5. V.R.T.

    MRC/NIHR DecodeME Showcase meeting online and in person Nov 6th

    So we need to link up with researchers and charities and figure out what important questions we need answers to that researchers are struggling to get funding to study? And design individual campaigns fundraising specifically for those studies? Maybe it could work for a couple of projects if...
  6. V.R.T.

    MRC/NIHR DecodeME Showcase meeting online and in person Nov 6th

    Thats very disappointing about the MRC if it turns out to be the case. I was hoping JE was told correctly about a change in attitude. Perhaps it is a good idea to prepare for the worst then? Have a serious try to scale up fundraising efforts. Surely the worst that can happen if we succeed is...
  7. V.R.T.

    MRC/NIHR DecodeME Showcase meeting online and in person Nov 6th

    Maybe some findings from WILCO? He's a STIMULATE ICP investigator right? This is happening on my birthday so I probably won't be watching but I'm quite interested in what Altmann has to say.
  8. V.R.T.

    MRC/NIHR DecodeME Showcase meeting online and in person Nov 6th

    70 in person and 50 online tickets seems tiny to me, am I wrong?
  9. V.R.T.

    Preprint Mechanisms of sex differences in acute and long COVID sequelae in mice, 2025, Liu et al.

    This would seem to be more evidence against viral persistance driving symptoms then. If only we could get the US LC research lot to listen... But were these found during autopsies of the mice and/or in tissues that can't safely be tested in live humans?
  10. V.R.T.

    Do you have small fiber neuropathy (SFN)?

    I have many symptoms of SFN but have never had a biopsy
  11. V.R.T.

    United Kingdom: Action for ME's PRIME project - research infrastructure

    I also appreciated the way he framed it as 'we need to accelerate ME research towards effective treatments and diagnostics'. I think so much emphasis is often put by researchers on biomarkers and tests that you question whether they understand what the real priority is. Whereas when they...
  12. V.R.T.

    United Kingdom: Action for ME's PRIME project - research infrastructure

    Iirc Chris also said they would meet once a week? It sounds like exactly what ME research in this country needs. Some unity and direction. I'm particularly excited by the possibility of new specialists in DecodeME gene areas getting involved.
  13. V.R.T.

    Who will pursue treatments for low NK cell patients?

    Sounds like if it's CD38 inhibition rather than plasma cell depletion we want this drug might be more effective than daratumumab?
  14. V.R.T.

    Who will pursue treatments for low NK cell patients?

    Interesting! If this is the case then the Scheibenbogen trial will be worth keeping an eye on if it goes ahead. I hope they measure NK cells before treatment too.
  15. V.R.T.

    Preprint Initial findings from the DecodeME genome-wide association study of myalgic encephalomyelitis/chronic fatigue syndrome, 2025, DecodeMe Collaboration

    Besides SequenceME, is it possible/practical for someone to do a study focussing on all or some of these genes? My understanding is that you don't need anywhere near as many participants for statistical significance when you are looking at a specific gene rather than at the genome as a whole. It...
  16. V.R.T.

    Trial Report Plasma cell targeting with the anti-CD38 antibody daratumumab in ME/CFS -a clinical pilot study, 2025, Fluge et al

    Isnt that the one thats in Polar Bear livers thats toxic to humans? Answered my own question - yes, in high quantities. https://en.wikipedia.org/wiki/Hypervitaminosis_A
  17. V.R.T.

    Who will pursue treatments for low NK cell patients?

    Does the anti CD38 drug Scheibenbogen is using also require NK cells to work? Do you have any speculations about what sort of approach the other subgroup might need in this scenario?
  18. V.R.T.

    Who will pursue treatments for low NK cell patients?

    I assume this stuff will be investigated after dara p2 if it succeeds but that is a way off. Personally I wish they could have gone straight to a larger phase 3 with mostly high nk cell patients but subgroups of artificially raised and low NK cell patients. If there trial is postive and it was...
  19. V.R.T.

    Development and validation of blood-based diagnostic biomarkers for [ME/CFS] using EpiSwitch®… 2025, Hunter et al. (Oxford Biodynamics)

    Every time someone does this it plays into BPS hands! Can't researchers understand that by constantly announcing they have found a biomarker based on premature and in this case poorly conducted findings it delegitamises them AND us in the eyes of the medical establishment.
  20. V.R.T.

    Efgartigimod (Vyvgart) - what could the trial data possibly tell us?

    If they truly believe the drug helped them, and the drug company are refusing to release the data, what else can they do but call for another trial?
Back
Top Bottom